

## **ObsEva SA to Participate in Jefferies Global Healthcare Conference**

**June 5-8, 2018**

**Geneva, Switzerland and Boston, MA –May 31, 2018** – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that company management will participate in the Jefferies Global Healthcare Conference taking place from June 5-8, 2018, in New York City.

ObsEva will be presenting on Tuesday, June 5<sup>th</sup>, 2018, at 3:00 p.m. Eastern Time (EST). A webcast will be available in the "Investors" section of ObsEva's website [www.ObsEva.com](http://www.ObsEva.com).

### **About ObsEva**

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit [www.ObsEva.com](http://www.ObsEva.com).

###

### **Media Contact:**

Marion Janic  
RooneyPartners LLC  
[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)  
+1 212-223-4017

### **Company Contact:**

CEO Office contact  
Shauna Dillon  
[Shauna.dillon@obseva.ch](mailto:Shauna.dillon@obseva.ch)  
+41 22 552 1550

### **Investor Contact**

Mario Corso  
Senior Director, Investor Relations  
[mario.corso@obseva.com](mailto:mario.corso@obseva.com)  
+1 857-972-9347 office  
+1 781-366-5726 mobile